Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Circon/U.S. Surgical

This article was originally published in The Gray Sheet

Executive Summary

Circon/U.S. Surgical: Circon shareholders elect two USSC-nominated board members to Circon's seven member board of directors in furtherance of USSC's hostile bid to take over the firm, according to a preliminary tabulation of Circon's Oct. 6 shareholder vote by independent inspector of the election Corporation Trust Company. Circon shareholders also appear to have adopted a USSC-sponsored, non-binding resolution to auction Circon to the highest bidder. Circon in late August rejected USSC's most recent tender offer of $16.50 per share, which will expire Oct. 23. USSC's first effort to buy Circon was an $18-per-share bid in August 1996. USSC has filed suit against Circon seeking to enjoin the company from reappointing Chairman and CEO Richard Auhll to the board ("The Gray Sheet" Sept. 22, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel